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There is now a large body of evidence that platelets are central actors of inflammatory reac-
tions. Indeed, platelets play a significant role in a variety of inflammatory diseases. These
diseases include conditions as varied as atherosclerosis, arthritis, dermatitis, glomeru-
lonephritis, or acute lung injury. In this context, one can note that inflammation is a
convenient but imprecise catch-all term that is used to cover a wide range of situations.
Therefore, when discussing the role of platelets in inflammation, it is important to clearly
define the pathophysiological context and the exact stage of the reaction. Inflammatory
reactions are indeed multistep processes that can be either acute or chronic, and their
sequence can vary greatly depending on the situation and organ concerned. Here, we
focus on how platelets contribute to inflammatory reactions involving recruitment of neu-
trophils and/or macrophages. Specifically, we review past and recent data showing that
platelets intervene at various stages of these reactions to regulate parameters such as
endothelial permeability, the recruitment of neutrophils and macrophages and their effec-
tor functions, as well as inflammatory bleeding.The mechanisms underlying these various
modulating effect of platelets are also discussed.
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PLATELETS CONTROL ENDOTHELIAL PERMEABILITY AND
LEUKOCYTE INFILTRATION
While platelets have long been known to promote the semi-
permeable barrier function of the resting endothelium (1), it
has become equally clear that under inflammatory conditions,
platelets can promote vascular permeability. Indeed, both edema
formation and leukocyte infiltration have been shown to be
markedly reduced by thrombocytopenia in multiple models of
acute or chronic inflammation. For instance, immunodepletion
of platelets was shown to inhibit neutrophil extravasation and the
efflux of Evans blue from mesenteric venules in a mouse model
of thioglycollate-induced peritonitis (2). Thrombocytopenia also
resulted in reduced skin edema and infiltration of neutrophils,
eosinophils, and mast cells in models of cutaneous leukocyto-
clastic vasculitis (3) and of chronic contact hypersensitivity (4).
These pro-inflammatory effects of platelets were also reported in
the inflamed lungs (5–7), the very same organ where the anti-
permeability effect of platelets was demonstrated in unchallenged
thrombocytopenic animals (8).
Notably, while in the above-cited examples the efflux of leuko-
cytes and plasma were both promoted by platelets, situations where
only one of these parameters was impacted by platelet depletion
have also been reported. In a mouse model of irritant contact
dermatitis, experimental thrombocytopenia led to reduced edema
formation without affecting neutrophil infiltration (9). Platelet
depletion also resulted in complete abrogation of protein leak-
age without affecting neutrophil recruitment to the lungs in a
model of transfusion-related acute lung injury (7). Concordantly,
thrombocytopenia fully prevented endothelial gap formation and
vascular leakage during experimental arthritis but only partially
reduced the overall arthritis severity (10). Therefore, although
promotion of plasma and leukocyte extravasation by platelets
may share common mechanistic aspects, they are clearly distinct
parameters with their own distinct regulatory mechanisms. Inter-
estingly, it was recently shown that leukocyte extravasation and
vascular permeability can be controlled separately by different
tyrosine residues of VE-cadherin (11). Whether such a mechanism
contributes to differential regulation of vascular permeability and
leukocyte infiltration by platelets remains to be demonstrated but
these results suggest that distinct and selective regulation of these
two parameters is possible at the endothelial junction level.
Recruitment of platelets to the inflamed vasculature and local
release of soluble compounds from activated platelets likely con-
stitute the predominant basic mechanisms common to regula-
tion of both vascular permeability and leukocyte extravasation
by platelets. Interactions between platelets and inflamed vessels
have been shown to be an early event in various models of
acute and chronic inflammation (7, 9, 10, 12–19). Various adhe-
sion receptors can support the early recruitment of platelets to
inflamed microvessels and the subsequent actions of platelets on
vascular permeability and leukocyte extravasation. The nature of
these receptors is highly dependent on the inflammatory con-
text. While platelet P-selectin was crucial for platelet recruitment
and leukocyte extravasation in experimental colitis (20), acute
lung injury (5), chronic cutaneous hypersensitivity (4), allergic
asthma (21), glomerulonephritis (17), and cerebral and intestinal
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ischemia/reperfusion (13, 14), it played only a minor role in the
recruitment of neutrophils in thioglycollate-induced peritonitis
(2). Likewise, GPIb was critical for platelet recruitment and leuko-
cyte invasion at atheromatous lesion-prone sites in hypercholes-
terolemic mice (12) and during peritonitis (2) but dispensable for
early recruitment of platelets to the inflamed glomerulus (19).
In addition to P-selectin and GPIb, GPVI, GPIIb–IIIa, CD40L
are among the other platelet receptors that have been reported
to be involved in platelet recruitment and action on vascular
permeability and/or leukocyte recruitment (Table 1).
Remarkably, immunohistological and intravital analyses have
revealed that platelet recruitment during the early phase of the
inflammatory reaction mostly occurs through transient and firm
adhesion of individual platelets to endothelial cells and gaps in
the endothelial lining, and/or to adherent leukocytes rather than
through platelet aggregation and thrombus formation (7, 9, 10,
12–14, 16, 18–20). Binding of platelets to adherent leukocytes
illustrates the fact that while platelets support the recruitment
of leukocytes during inflammatory reactions, the opposite is also
true. Inhibition of neutrophil recruitment by immunodepletion
of neutrophils or by pharmacological or genetic targeting of
their adhesion receptors was indeed shown to induce a reduc-
tion in platelet recruitment in various inflammation models (7,
13, 14, 19, 27). It is also noteworthy that interactions between
activated platelets and leukocytes do not only occur at the inflam-
matory site but also in the circulation. The signals triggered by
these interactions notably induce integrin activation, thus priming
leukocytes for adhesion to inflamed vessels (24, 28). Increased for-
mation of neutrophil/platelet and/or monocyte/platelet complexes
has been reported in patients with various inflammatory dis-
eases including rheumatoid and psoriatic arthritis (29–31), allergic
asthma (32), perionditis (33), ulcerative colitis (34), ischemic
stroke (35), dengue infection (36), and atherosclerosis (37). Con-
sidering the contribution of platelet/leukocyte interactions to the
pathogenesis of various inflammatory diseases in experimental
models, in part, via promotion of neutrophil infiltration, increased
platelet/leukocyte complexes in human diseases may not only
reflect platelet activation but also participate in disease regulation.
Table 1 | Regulation of vascular permeability and leukocyte recruitment by platelets.
Inflammatory model Receptors and/or
soluble factors involved
References
Vascular permeability Arthritis GPVI/Serotonin Cloutier et al. (10)
Peritonitis GPIb/vWF Petri et al. (2)
Leukocytoclastic vasculitis P-selectin/PSGL-l Hara et al. (3)
Chronic cutaneous hypersensitivity ND Tamagawa-Mineoka et al. (4)
Acute lung inflammation P-selectin Hidalgo et al. (7), Zarbock et al. (5)
Leukocyte recruitment Glomerulonephritis P-selectin/PSGL-1 Kuligowski et al. (17)
P-selectin Devi et al. (19)
Atherosclerosis GPVI/EMMPRIN Schulz et al. (22)
CD40L and MCP-l Lievens et al. (23)
GPIb, GPIIbIIIa Massberg et al. (12)
P-selectin Huo et al. (24)
Cerebral I/R GPIIbIIIa Massberg et al. (15)
CD40/CD40L/sCD40L Ishikawa et al. (14)
Intestinal I/R P-selectin Ishikawa et al. (14)
Abdominal sepsis Serotonin Duerschmied et al. (25)
ND/Mac-1 Asaduzzaman et al. (6)
Peritonitis GPIb/vWF Petri et al. (2)
Serotonin Duerschmied et al. (25)
Experimental colitis CD40L Vowinkel et al. (20)
P-selectin/PSGL-1 Vowinkel et al. (20)
Aseptic wound Serotonin Duerschmied et al. (25)
Acute Lung inflammation Serotonin, TXA2, P-selectin Duerschmied et al. (25), Hidalgo et al. (7), Zarbock et al. (5)
Leukocytoclastic vasculitis P-selectin/PSGL-1 Hara et al. (3)
Chronic cutaneous hypersensitivity P-selectin Tamagawa-Mineoka et al. (4)
Allergic asthma P-selectin, Serotonin Pitchford et al. (21), Durk et al. (26)
Examples of various inflammatory situations in which platelets were shown to regulate vascular permeability and/or leukocyte recruitment. If identified, the adhesion
receptors and/or soluble factors involved are indicated. Platelet-derived factors are underlined.
CD40, cluster of differentiation 40, CD40L, cluster of differentiation 40 ligand, EMMPRIN, extracellular matrix metalloproteinase inducer, Mac-1, macrophage-1
antigen, MCP-1, monocyte chemoattractant protein-1, ND, non-determined, PAF, platelet-activating factor, PSGL-1, P-selectin glycoprotein ligand 1, sCD40L, soluble
cluster of differentiation 40 ligand, TXA2, thromboxane A2, VEGF, vascular endothelial growth factor, vWF, von Willebrand factor.
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The release of soluble factors by platelets is also central to
their ability to modulate endothelial permeability and leuko-
cyte infiltration. In the same way, platelets contain endothelial
barrier-enhancing factors [e.g., angiopoietin-1 and sphingosine-
1-phosphate (S1P)] (1), they also contain a large range of
chemokines, cytokines, and other soluble mediators capable of
loosening endothelial junctions and/or of activating or attracting
leukocytes. Among the platelet factors that can open interendothe-
lial junctions are factors that are not specific to platelets such
as vascular endothelial growth factor (38) or platelet-activating
factor (PAF) (39, 40), and serotonin, for which platelets are the
major peripheral source (41). In particular, platelet serotonin was
recently shown to mediate the GPVI-dependent pro-permeability
effect of platelets in inflamed joints during arthritis (10) and the
recruitment of neutrophils and/or eosinophils in various models
of acute inflammation (25, 26).
The panel of chemokines found in platelets is extensive
and includes platelet factor 4, stromal cell-derived factor-1,
macrophage inflammatory protein-1α (MIP-1α), regulated upon
activation, normal T cell expressed and secreted (RANTES), and
thymus and activation-regulated chemokine (TARC), to name but
a few (4, 24, 42). Like P-selectin, these chemokines are stored in
platelet granules and their contribution to recruitment of leuko-
cytes by platelets highlights the need for platelet activation in
this process. In agreement, ADP-dependent platelet activation was
required for glomerular recruitment of leukocytes by platelets
(19). Moreover,while some platelet-derived soluble factors directly
target endothelial cells and/or leukocytes, others like PAF, S1P,
and serotonin also target platelets themselves and could therefore
amplify their regulatory effects on vascular permeability and/or
leukocyte recruitment. Finally, another mechanism reported for
the stimulation of neutrophil recruitment by activated platelets
is the up-regulation of the expression of adhesion molecules on
the endothelium. Activated platelets were shown to increase the
expression of ICAM-1 and αvβ3 on endothelial cells through the
secretion of IL-1β (43), and to induce the secretion of Weibel–
Palade bodies (44). Importantly, together, these observations that
platelets can engage their adhesion receptors and release bioac-
tive factors independently of aggregation substantiate the concept
that platelet activation is a finely tuned and graduated process that
allows context-dependent responses (27, 45–48).
PLATELETS REGULATE NEUTROPHIL AND MACROPHAGE
EFFECTOR FUNCTIONS
Many studies have demonstrated the ability of platelets to regulate
most of the effector functions of neutrophils and macrophages
such as the production of reactive oxygen species (ROS), the
secretion of neutrophil granule content, phagocytosis, or the
formation of neutrophil extracellular traps (NETs). Thrombin-
activated platelets were shown to stimulate the respiratory burst
in unstimulated monocytes and neutrophils in vitro (49–51).
Zalavary et al. showed that resting platelets enhanced the respi-
ratory burst of neutrophils stimulated with IgG-opsonized yeast
particles (52). However, the opposite effect was found when
the chemoattractant formyl-methionyl-leucyl-phenylalanine was
used as an agonist (53–56). The fact that the pro- or anti-ROS
effect of platelets depends on experimental conditions such as
the platelet and neutrophil agonists used again highlights how
the action of platelets may ultimately be context-dependent. Sev-
eral non-mutually exclusive mechanisms have been proposed to
support the modulation of the oxidative burst in innate immune
cells by platelets. The release of adenine nucleotide derivatives by
platelets has been consistently shown to inhibit ROS generation
in neutrophils (49, 53, 54). Evidence that direct cell–cell contact
between platelets and monocytes/neutrophils is also important for
regulation of the oxidative burst in these cells has also been pro-
vided. Prevention of platelet adhesion to neutrophils was indeed
shown to suppress the modulatory effect exerted by platelets on
ROS generation by neutrophils, whether it was stimulatory (50,
51, 54, 57, 58) or inhibitory (58). In vivo data on the actual
contribution of platelets to modulation of ROS generation by
innate immune cells during inflammatory reactions are, however,
scarce. Nevertheless, binding of platelets to adherent neutrophils
induced the generation of ROS by neutrophils in a mouse model of
transfusion-related acute lung injury (7), a mechanism that might
contribute to vascular damage and lung injury. Stimulation of
the neutrophil respiratory burst by platelets was also proposed
to contribute to proteinuria during immune-complex-induced
experimental glomerulonephritis (51), as ROS were previously
shown to be one of the main causes of glomerular damage in
this model (59).
Several in vitro studies have shown that platelets can inhibit
the release of myeloperoxidase and neutrophil elastase (57, 60).
In contrast, platelets amplified lysozyme secretion by neutrophils
stimulated with opsonized zymosan (61, 62). It is likely that as
for ROS generation and endothelial permeability, platelets reg-
ulate neutrophil degranulation in a stimulus-specific manner.
Some groups have demonstrated that in addition to regulat-
ing neutrophil degranulation and ROS production, platelets can
also stimulate neutrophil phagocytosis by both contact-dependent
and contact-independent mechanisms (52, 57). More recently, it
was shown that the uptake of oxidized low-density lipoproteins
(OxLDL) by monocytes was increased by direct platelet–monocyte
interactions in vitro and in vivo (63). These findings partly echoed
those of previous studies with the difference that the earlier stud-
ies focused on the ability of platelet secretion products to enhance
macrophage uptake of OxLDL (64–66).
The production and release of cytokines by monocytes can
also be regulated by platelets. Thrombin-activated platelets were
shown to induce expression and secretion of MCP-1 and IL-
8 by monocytes in a P-selectin-dependent manner (67). The
contribution of P-selectin-mediated platelet–monocyte interac-
tions to cytokine responses was recently investigated in patients
with dengue infection. Whereas P-selectin-dependent binding of
platelets from patients with dengue to monocytes from healthy
volunteers induced the secretion of the IL-1β, IL-8, IL-10, and
MCP-1, platelets from healthy volunteers only induced the secre-
tion of MCP-1 (36). Modulation of cytokine levels by platelets
was also reported in the cecal ligation and puncture mouse model
of sepsis, a model in which deficiency in platelet GPIbα led to
reduced platelet–monocyte and platelet–neutrophil interactions,
and to increased circulating levels of TNF-α, MCP-1, IL-6, and
MIP-1β (68). A substantial contribution of platelets to the reg-
ulation of systemic inflammatory responses was also shown in
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a model of pneumonia-derived sepsis (69) and in a model of
thermal injury (70). In this latter model, plasma levels of TNF-
α, IL-6, and MCP-1 were increased in thrombocytopenic mice,
which also displayed reduced levels of TGF-β compared to con-
trol mice. In line with these studies, it was shown that secretion
of PDGF by activated platelets was required for the release of
MCP-1 and subsequent monocyte infiltration and killing in tissues
infected with Leishmania parasites (71). It should be noted that
thrombocytopenia led to a higher mortality rate in sepsis and ther-
mal injury, and to reduced elimination of Leishmania parasites,
thus demonstrating an overall beneficial role of platelets in these
models. Thrombocytopenia also increased the mortality of mice
infected with encephalomyocarditis virus, a situation in which
platelet-TLR7-dependent formation of platelet–neutrophil aggre-
gates played a protective role (72). These various examples where
platelets exerted a beneficial effect under inflammatory conditions
in some way balance those where platelets were shown to play a
pathogenic role, as in glomerulonephritis (51), acute lung injury
(5), atherosclerosis (12, 15), and rheumatoid arthritis (10, 73).
Neutrophil extracellular traps are extracellular webs made of
DNA fibers decorated with neutrophil granule proteins that form
according to a specific cell death process (74, 75). The contri-
bution of platelets to NET formation was first demonstrated
by a series of experiments showing that TLR4- and integrin-
dependent platelet–neutrophil interactions led to the production
of NETs capable of trapping bacteria and also causing tissue dam-
age in models of endotoxemia and sepsis (27, 76). Stimulation of
NET formation by platelets has since been shown in models of
sterile acute lung injury where NETs contribute to lung endothe-
lial damage (77, 78). Importantly, while platelets stimulate NET
formation, in return, NETs cause platelet activation and aggrega-
tion, thus linking inflammation and thrombosis (79). This form
of thrombosis triggered by neutrophil–platelet interactions has
been called immunothrombosis and helps fight bacterial infection
(80, 81). The downside of immunothrombosis is that it can also
initiate deep vein thrombosis (82, 83) and contribute to cancer-
associated thrombosis (84). Finally, immunothrombosis illustrates
how interactions between platelets and leukocytes lead to recip-
rocal regulation, a notion previously introduced by earlier in vitro
studies showing the modulation of platelet reactivity and adhesion
properties by neutrophils and/or macrophages (48, 85–89).
PLATELETS PREVENT INFLAMMATORY BLEEDING
Inflammatory reactions have been identified as a cause of spon-
taneous bleeding during thrombocytopenia, thus demonstrating
that platelets also intervene to prevent bleeding during inflam-
mation. This protective role of platelets was notably established
in situations where platelets were also shown to promote vascular
permeability and/or leukocyte infiltration. For example, induction
of thrombocytopenia resulted in immediate and severe skin bleed-
ing during cutaneous leukocytoclastic vasculitis (90), the same
model in which it caused reduced skin edema and neutrophil
infiltration (3). Again, this highlights the duality of platelets that
can exert apparently opposed effects during the course of a given
inflammatory reaction. Nonetheless, though regulation of plasma
leakage and prevention of bleeding can both be referred to as main-
tenance of vascular integrity, the mechanisms underlying edema
formation and bleeding are essentially different. Opening of inter-
cellular junctions favors edema formation by allowing plasma fluid
and small molecules to filter out through endothelial gaps and
the basement membrane. Larger elements like platelets and red
blood cells are, however, retained by the vascular wall (91). For this
reason, injection of the pro-permeability factor vascular endothe-
lial growth factor (VEGF) did not cause any skin bleeding when
injected in thrombocytopenic mice (92). In a similar manner, mice
lacking the anti-permeability factor, S1P, in plasma exhibited basal
vascular leakage of proteins and fluid in the lungs, but no bleed-
ing (93). Therefore, while vascular permeability is tightly regu-
lated and controlled through modulation of endothelial junctions
bleeding implies vascular damage with rupture or distortion of the
basement membrane mesh. There is strong evidence suggesting
that neutrophils may cause this damage: in various inflamma-
tory models, bleeding in inflamed organs of thrombocytopenic
mice was prevented by depletion of neutrophils (18, 92). Preven-
tion of inflammatory bleeding by platelets most likely relies on
the inhibition or repair of neutrophil-dependent injury. Although
this is unlikely to provide the full explanation, this vasculoprotec-
tive action of platelets has been shown to be independent of their
ability to form thrombi. Indeed, it has been reported that platelet
interactions with inflamed microvessels occur before any sign of
thrombosis, and that prevention of this early initial platelet depo-
sition results in accelerated and exacerbated local hemorrhage (18,
90). Moreover, mice lacking platelet adhesion receptors required
for thrombus formation or with impaired G-protein coupled
receptor (GPCR) signaling in platelets have shown no bleeding
at sites of inflammation despite their compromised ability to form
platelet plugs and to ensure classical hemostasis (90, 94). A recent
study indicates that instead, the immunoreceptor tyrosine-based
activation motif (ITAM)-associated GPVI and C-type lectin-like
receptor-2 (CLEC-2) play a predominant role in the prevention
of inflammatory bleeding by platelets (94, 95). Given that GPVI is
the main platelet receptor for collagen, this suggests that platelets
could stop bleeding by covering small areas where the basement
membrane gets exposed and disrupted by recruited neutrophils.
Whereas non-aggregated adherent platelets could exert a purely
mechanical action by plugging small holes in the endothelial lin-
ing, recent results suggest that the release of soluble factors by
platelets could further help seal vessel lesions induced by neu-
trophils. We have shown that even when not causing aggregation,
engagement of GPVI by collagen leads to the release of soluble
platelet factors capable of tightening interendothelial junctions
such as angiopoietin-1 (48). Furthermore, platelets lacking the
adapter protein SLP-76, which mediates GPVI-dependent platelet
responses to collagen including degranulation and spreading, were
shown to be unable to prevent inflammatory bleeding (94). Also,
although absence of S1P is not in itself a cause of bleeding, it
was shown to sensitize peripheral lymph nodes to bleeding in a
mouse model of immunization characterized by high lymphocyte
trafficking (95). Whether this protective role of S1P and, more
specifically, of platelet S1P also applies to other inflammatory
models remains to be verified but in any case, results from this
study indicate that factors stimulating closure of interendothe-
lial junctions can help stop bleeding associated with leukocyte
trafficking.
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FIGURE 1 | Platelets are integral players of inflammatory reactions.
(A) During the early phase of inflammatory reactions, platelets are recruited
to inflamed vessels and enhance vascular permeability by secreting
pro-permeability factors such as serotonin, vascular endothelial growth factor
A (VEGF-A), or platelet-activating factor (PAF). Platelets further enhance the
recruitment and infiltration of leukocytes by secreting chemokines [e.g.,
activation or normal T cell expressed and secreted (RANTES) or platelet factor
4 (PF-4)], and by upregulating the expression and/or activation of adhesion
molecules on leukocytes and endothelial cells via direct cell–cell contacts and
secretion of pro-inflammatory cytokines. The platelet receptors (e.g., GPVI,
GPIb, GPIIbIIIa, or P-selectin) supporting the interactions of platelets with
inflamed vessels and/or leukocytes vary with the organ and inflammatory
reactions concerned. (B) Platelets can modulate various leukocyte effector
functions: toll-like receptor 4 (TLR4)-dependent activation of platelets
promotes the formation of antibacterial neutrophil extracellular traps (NETs);
platelets can also either stimulate or inhibit the production of reactive oxygen
species (ROS) and/or secretion of cytokines and cytotoxic enzymes [e.g.,
myeloperoxidase (MPO), serine proteases] by neutrophils and macrophages
depending on the inflammatory situation; platelets can stimulate
phagocytosis and thus enhance foam cell formation by promoting the uptake
of oxidized low-density lipoprotein by monocytes/macrophages (oxLDL).
(C) Platelets prevent bleeding associated with leukocyte trafficking. This
protective action of platelets has been shown to be independent of thrombus
formation and to rely on the engagement of platelet ITAM receptors, which
might cause secretion of anti-permeability factors such as angiopoietin-1
(Ang1) and sphingosine-1-phosphate (S1P) by platelets.
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The ITAM-dependent vasculoprotective action of platelets
could also depend on their interactions with leukocytes. As
mentioned above, platelets recruited to inflamed vessels bind to
adherent leukocytes. The extracellular matrix metalloproteinase
inducer (EMMPRIN) was recently identified as a counter-receptor
for GPVI and is present on neutrophils and macrophages (22,
96). Additionally, podoplanin, the ligand for CLEC-2, is absent
on blood endothelial cells but is expressed by inflammatory
macrophages (97). ITAM-mediated interactions between platelets
and innate immune cells thus represent another potential trigger
for the anti-permeability and/or“neutrophil-dampening”effect of
platelets.
In conclusion, all these data showing that in a given situation,
platelets can intervene to regulate vascular permeability, leukocyte
infiltration, and effector functions, as well as bleeding associated
with leukocyte trafficking, demonstrate that platelets are integral
players of inflammatory reactions (Figure 1). Also, it appears
that the pro- or anti-inflammatory character of platelets is highly
dependent on parameters such as the cause of inflammation,
which defines the pathways and extent of leukocyte, platelet, and
endothelial cell activation, and the stage and/or endpoint readouts
of the inflammatory reaction considered. In a similar manner, the
overall impact of platelets on inflammatory diseases can either be
beneficial or deleterious depending on the pathophysiological situ-
ation. Finally, as illustrated by the increasing interest in platelets as
potential targets for the treatment of allergic inflammation (26, 98,
99), the availability of numerous anti-platelet drugs could open up
new therapeutic perspectives for the many inflammatory diseases
where platelets have been shown to play a pathogenic role (100).
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